Companies Jasper Therapeutics, Inc.
Jasper Therapeutics (JSPR): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Email me Jasper Therapeutics, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $3,369,990FY2023
- $3,215,003FY2024
CEO total pay was $3,215,003 in fiscal 2024, down from $3,369,990 in fiscal 2023.
FY2024: salary $727,272 · bonus $0 · stock awards $438,000 · option awards $1,740,640
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ronald Martell | $727,272 | $0 | $438,000 | $1,740,640 | $309,091 | $0 | $0 | $3,215,003 |
| President and Chief Executive Officer | ||||||||
| Edwin Tucker | 514,500 | 0 | 0 | 689,324 | 196,796 | 0 | 0 | 1,400,620 |
| Chief Medical Officer | ||||||||
| Jeet Mahal | 481,301 | 0 | 0 | 612,732 | 184,098 | 0 | 0 | 1,278,131 |
| Chief Operating Officer | ||||||||
| Herb Cross | 476,100 | 0 | 0 | 612,732 | 182,108 | 0 | 0 | 1,270,940 |
| Chief Financial Officer and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Ronald Martell | $3,215,003 | $3,369,990 | — | ↓ −154,987 |
| Edwin Tucker | 1,400,620 | 977,726 | — | ↑ +422,894 |
| Jeet Mahal | 1,278,131 | 1,184,707 | — | ↑ +93,424 |
| Herb Cross | 1,270,940 | 643,122 | — | ↑ +627,818 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Jasper Therapeutics designs compensation programs to attract, retain, incentivize, and reward deeply talented executives who share the company's philosophy. The programs are intended to promote company success and align executive incentives with the long-term interests of stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Ronald Martell | OPTION | 2024-02-15 | — | — | 100,000 | — | — |
| Herb Cross | OPTION | 2024-02-15 | — | — | 40,000 | — | 612,732 |
| Jeet Mahal | OPTION | 2024-02-15 | — | — | 40,000 | — | 612,732 |
| Ronald Martell | OPTION | 2024-06-10 | — | — | 10,000 | — | — |
| Ronald Martell | PRSU | 2024-06-10 | — | 20,000 | — | — | — |
| Edwin Tucker | OPTION | 2024-02-15 | — | — | 45,000 | — | 689,324 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Herb Cross | $0 | $0 | $612,732 | 0.0% |
| Jeet Mahal | 0 | 0 | 612,732 | 0.0% |
| Edwin Tucker | 0 | 0 | 689,324 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jeet Mahal | Option | 187 | 35.4 | — |
| Jeet Mahal | Option | 693 | 31.2 | — |
| Jeet Mahal | Option | 2,730 | 35.4 | — |
| Ronald Martell | Option | 10,000 | 23.95 | — |
| Jeet Mahal | Option | 19,689 | 18.7 | — |
| Ronald Martell | PSU | 20,000 | — | 427,600 |
| Edwin Tucker | Option | 25,000 | 16.2 | — |
| Ronald Martell | Option | 28,130 | 18.7 | — |
| Herb Cross | Option | 37,812 | 7.8 | — |
| Herb Cross | Option | 40,000 | 17.95 | — |
| Jeet Mahal | Option | 40,000 | 17.95 | — |
| Edwin Tucker | Option | 45,000 | 17.95 | — |
| Ronald Martell | Option | 53,259 | 35.4 | — |
| Ronald Martell | Option | 59,250 | 17.8 | — |
| Ronald Martell | Option | 100,000 | 17.95 | — |
Director compensation
No director compensation table is on file for fiscal year 2024.
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Peer group, and who names Jasper Therapeutics as a peer
Companies that benchmark against JSPR
2 companies name JSPR as a compensation peer
- ANAPTYSBIO, INCANABFY2025
- aTYR PHARMA INCATYRFY2025
Each company listed discloses JSPR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named JSPR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Jasper Therapeutics, Inc. | 2024 | Ronald Martell | $727,272 | $438,000 | $1,740,640 | $309,091 | $3,215,003 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (13 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Ronald Martell. DEF 14A, filed 2025-05-19. Section “Executive Compensation”. As printed: 3,215,003. View filing ↗
- Section 01, Edwin Tucker. DEF 14A, filed 2025-05-19. Section “Executive Compensation”. As printed: 1,400,620. View filing ↗
- Section 01, Jeet Mahal. DEF 14A, filed 2025-05-19. Section “Executive Compensation”. As printed: 1,278,131. View filing ↗
- Section 01, Herb Cross. DEF 14A, filed 2025-05-19. Section “Executive Compensation”. As printed: 1,270,940. View filing ↗
- Section 03, Ronald Martell OPTION. DEF 14A, filed 2025-05-19. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Herb Cross OPTION. DEF 14A, filed 2025-05-19. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jeet Mahal OPTION. DEF 14A, filed 2025-05-19. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Ronald Martell OPTION. DEF 14A, filed 2025-05-19. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Ronald Martell PRSU. DEF 14A, filed 2025-05-19. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Edwin Tucker OPTION. DEF 14A, filed 2025-05-19. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Jasper Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-05-19. CEO total compensation as printed in Jasper Therapeutics, Inc.'s own proxy. As printed: 3,215,003. View filing ↗